When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity
International Journal of Cancer · 2024-08 · 155 (3) · 384-399
DOI: 10.1002/ijc.34954 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 24.04.2024. Verfasst von Dong Pan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Medicine, School of Public Health, Wenzhou Medical University, Wenzhou, Zhejiang, China. Hauptthemen laut MEDLINE: DNA Damage, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 119 Literaturangaben. Gefördert von: Wenzhou Medical University, Department of Science and Technology of Zhejiang Province, Wenzhou Science and Technology Bureau.
Abstract (Originalsprache)
DNA damage is a prevalent phenomenon in the context of cancer progression. Evidence suggests that DNA damage responses (DDR) are pivotal in overcoming tumor immune evasion. Alternatively, traditional radiotherapy and chemotherapy operate by inducing DNA damage, consequently stimulating the immune system to target tumors. The intricate interplay between signaling pathways involved in DDR and immune activation underscores the significance of considering both factors in developing improved immunotherapies. By delving deeper into the mechanisms underlying immune activation brought on by DNA damage, it becomes possible to identify novel treatment approaches that boost the anticancer immune response while minimizing undesirable side effects. This review explores the mechanisms behind DNA damage‐induced antitumor immune responses, the importance of DNA damage in antitumor immunity, and potential therapeutic approaches for cancer immunotherapy targeting DDR. Additionally, we discuss the challenges of combination therapy and strategies for integrating DNA damage‐targeting therapies with current cancer immunotherapy. In summary, this review highlights the critical role of DNA damage in tumor immunology, underscoring the potential of DDR inhibitors as promising therapeutic modalities for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Medicine, School of Public Health, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Department of Dermatology, Duke University Medical Center, Durham, North Carolina, USA.
- Zhejiang Engineering Research Center for Innovation and Application of Intelligent Radiotherapy Technology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Zhejiang Provincial Key Laboratory of Watershed Sciences and Health, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Wenzhou Key Laboratory of Basic Science and Translational Research of Radiation Oncology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada.
ORCID-Profile: Qi Wang
Förderung
- Wenzhou Medical University
- Department of Science and Technology of Zhejiang Province
- Wenzhou Science and Technology Bureau
- Wenzhou Municipal Science and Technology Bureau
Zitieren
APA
Pan, D., Wang, Q., Shen, A., Qi, Z., Zheng, C., & Hu, B. (2024). When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity. International Journal of Cancer, 155(3), 384-399. https://doi.org/10.1002/ijc.34954
Vancouver
Pan D, Wang Q, Shen A, Qi Z, Zheng C, Hu B. When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity. International Journal of Cancer. 2024;155(3):384-399. doi:10.1002/ijc.34954
BibTeX
@article{Pan2024,
author = {Pan, Dong and Wang, Qi and Shen, Aihua and Qi, Zhihao and Zheng, Chunfu and Hu, Burong},
title = {When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity},
journal = {International Journal of Cancer},
year = {2024},
volume = {155},
number = {3},
pages = {384--399},
doi = {10.1002/ijc.34954}
}
EUVIMED